Bijoy K Menon (@bijoymenon) 's Twitter Profile
Bijoy K Menon

@bijoymenon

Stroke Physician, Trialist, Imager, Bumbling Parent, Student of Investing and Life

ID: 73911072

linkhttps://www.linkedin.com/in/bijoy-menon-b321776/?originalSubdomain=ca calendar_today13-09-2009 15:58:57

438 Tweet

751 Followers

333 Following

Stroke AHA/ASA (@strokeaha_asa) 's Twitter Profile Photo

As Dr Nerissa Ko mentioned, a stroke patient survivor reminded us why we do what we do. Dr William Mack with a grateful stroke patient who recovered speech after a healed carotid dissection. #ISC25

As Dr Nerissa Ko mentioned, a stroke patient survivor reminded us why we do what we do. Dr William Mack with a grateful stroke patient who recovered speech after a healed carotid dissection. #ISC25
Thanh Lam "Lance" Tran (@lance_tran_) 's Twitter Profile Photo

Dr Turc presenting at #ISC25 on thrombolytics in pts on DOACS, which in my understanding is more commonly than the states. 🧪Per ESOC guidelines, don't use PTT, but use Xa <0.5u/ml or TT for dabiga. 🏥This is supported by observational data.

Dr Turc presenting at #ISC25 on thrombolytics in pts on DOACS, which in my understanding is more commonly than the states. 

🧪Per ESOC guidelines, don't use PTT, but use Xa &lt;0.5u/ml or TT for dabiga.
🏥This is supported by observational data.
Johanna Seiden, MD MPH (@johannaseidenmd) 's Twitter Profile Photo

BEST trial: In a Phase 2 trial, BXOS110, a novel PSD-95 protein inhibitor administered within 3 hours after stroke onset demonstrated potential for improvement in functional outcomes (mRS 0-2 at 90 days) after stroke, paving the way for Phase 3 study in the future. #ISC25 #aha

BEST trial: In a Phase 2 trial, BXOS110, a novel PSD-95 protein inhibitor administered within 3 hours after stroke onset demonstrated potential for improvement in functional outcomes (mRS 0-2 at 90 days) after stroke, paving the way for Phase 3 study in the future. 

#ISC25 #aha
Guido J. Falcone MD, ScD, MPH (@guidofalconemd) 's Twitter Profile Photo

Very proud of this guy ... CONGRATULATIONS Cyprien Rivier ! ! ! For receiving the Vascular Cognitive Impairment Award @ #ISC25 for the abstract "Integrated Genomic/Proteomic Profiling Supports Cathepsin-B as a Drug Target in CSVD” isc.hub.heart.org/daily-coverage… Yale Neurology

Very proud of this guy ...

CONGRATULATIONS <a href="/CyprienRivier/">Cyprien Rivier</a> ! ! !  

For receiving the Vascular Cognitive Impairment Award @ #ISC25 for the abstract "Integrated Genomic/Proteomic Profiling Supports Cathepsin-B as a Drug Target in CSVD” 

isc.hub.heart.org/daily-coverage…

<a href="/NeurologyYale/">Yale Neurology</a>
Bijoy K Menon (@bijoymenon) 's Twitter Profile Photo

One cannot have asked for a better Chair than LaurenHSansing! Me and the entire program committee have loved her leadership and how much she cares! Excited for #ISC2026 at New Orleans! AHA Science

Umberto Pensato 🇮🇹 🇨🇦 (@upensato) 's Twitter Profile Photo

Neuroprotection is effective when administered in a specific time interval (it can prevent only infarct growth between administration and recanalization). Kudos to Mayank Goyal Johanna Ospel, MD PhD Michael D Hill Bijoy K Menon thelancet.com/journals/laneu…

Aravind Ganesh (@draravindganesh) 's Twitter Profile Photo

🚨In this prespecified analysis of the AcT RCT, we examined safety & efficacy outcomes of thrombolysis with tenecteplase & alteplase in elderly patients. 23% mRS 0-1 among >=80y vs 43% <80y. No difference in sICH. ahajournals.org/doi/10.1161/ST… nishita singh DCNS Calgary Bijoy K Menon

LaurenHSansing (@laurenhsansing) 's Twitter Profile Photo

Calling all stroke researchers and clinicians!! Deadline for invited symposia suggestions for #ISC26 in New Orleans is Thursday, April 3, 2025 at 6:00 a.m. ET! New categories!! Get your ideas into the conference :) AHA Science Bijoy K Menon Shadi Yaghi Dr. Lee Schwamm

Aravind Ganesh (@draravindganesh) 's Twitter Profile Photo

🚨In focus groups for ACT-GLOBAL, our ongoing stroke adaptive platform trial, patients & caregivers supported APT design but identified priorities re: execution to safeguard patient autonomy & safety doi.org/10.1159/000546… Bijoy K Menon Karger Publishers DCNS Calgary The George Institute for Global Health

🚨In focus groups for ACT-GLOBAL, our ongoing stroke adaptive platform trial, patients &amp; caregivers supported APT design but identified priorities re: execution to safeguard patient autonomy &amp; safety doi.org/10.1159/000546… <a href="/bijoymenon/">Bijoy K Menon</a> <a href="/KargerPublisher/">Karger Publishers</a> <a href="/DCNSNeuro/">DCNS Calgary</a> <a href="/georgeinstitute/">The George Institute for Global Health</a>
Seemant Chaturvedi (@chaturvedineuro) 's Twitter Profile Photo

The Symptomatic Carotid Outcomes Registry (SCORE) has now enrolled 2/3 of the target patient number. Planning to complete enrollment by the end of 2025. Let's keep the momentum going! Look for the poster at #ESOC2025 Thanh Nguyen 🇺🇦 Luciano Sposato 🇦🇷🇨🇦 Bijoy K Menon European Stroke Org American Academy of Neurology